Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function

Pulmonary Hypertension Clinical Trial

— STIMULATE  

Official title:

Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function (STIMULATE): A Single-center, Retrospective Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06186713
• Other study ID #: XJTU1AF2023LSK-406
• Status: Completed
• Start date: March 30, 2023
• Est. completion date: August 1, 2023

Study information

• Verified date: December 2023
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pulmonary hypertension (PH) has a negative effect on acute myocardial infarction (AMI) patients and appears to be closely associated with reduced left ventricular function. However, its impact on AMI patients with reduced left ventricular function remains unclear. This retrospective study included AMI patients with reduced left ventricular function to investigate the prognostic value of PH in this specific type of patient. Meanwhile, a nomogram would be established basing on the identified independent risk factors, hoping to provide a novel risk stratification for them.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4784
• Est. completion date: August 1, 2023
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The patients who were hospitalized for AMI with reduced left ventricular function at the First Affiliated Hospital of Jiaotong University from January 2018 to January 2022.

Exclusion Criteria:

• Myocardial infarction complicated by cardiac rupture.

• Significant pre-existing heart failure.

• Other comorbidities such as malignancy that may significantly affect prognosis.

• Incomplete clinical data.

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Hypertension
• Hypertension, Pulmonary
• Infarction
• Myocardial Infarction
• Pulmonary Hypertension

Intervention

Other:
• This was an observational study, and no Intervention was given to the patients.
This was an observational study, and no Intervention was given to the patients.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Xian Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of all-cause death	All-cause death will be determined by clinical records or phone calls with patients and their family.	1-year after the AMI.